Cargando…

Impact of Omalizumab in Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study

Most patients with asthma can control their symptoms with a basic standard of medical care and with maintenance and rescue medication. However, between 5% and 10% of asthmatics worldwide do not achieve control of their symptoms and have recurrent exacerbations and respiratory difficulties. The objec...

Descripción completa

Detalles Bibliográficos
Autores principales: Rojo-Tolosa, Susana, González-Gutiérrez, María Victoria, Sánchez-Martínez, José Antonio, Jiménez-Gálvez, Gonzalo, Pineda-Lancheros, Laura Elena, Gálvez-Navas, José María, Jiménez-Morales, Alberto, Pérez-Ramírez, Cristina, Morales-García, Concepción
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962091/
https://www.ncbi.nlm.nih.gov/pubmed/36839845
http://dx.doi.org/10.3390/pharmaceutics15020523
_version_ 1784895917803962368
author Rojo-Tolosa, Susana
González-Gutiérrez, María Victoria
Sánchez-Martínez, José Antonio
Jiménez-Gálvez, Gonzalo
Pineda-Lancheros, Laura Elena
Gálvez-Navas, José María
Jiménez-Morales, Alberto
Pérez-Ramírez, Cristina
Morales-García, Concepción
author_facet Rojo-Tolosa, Susana
González-Gutiérrez, María Victoria
Sánchez-Martínez, José Antonio
Jiménez-Gálvez, Gonzalo
Pineda-Lancheros, Laura Elena
Gálvez-Navas, José María
Jiménez-Morales, Alberto
Pérez-Ramírez, Cristina
Morales-García, Concepción
author_sort Rojo-Tolosa, Susana
collection PubMed
description Most patients with asthma can control their symptoms with a basic standard of medical care and with maintenance and rescue medication. However, between 5% and 10% of asthmatics worldwide do not achieve control of their symptoms and have recurrent exacerbations and respiratory difficulties. The objective of the study was the real-life evaluation of the clinical improvement of patients with severe eosinophilic asthma treated with omalizumab, together with the search for biomarkers associated with the response. An observational retrospective cohort study was conducted that included patients with severe uncontrolled allergic asthma being treated with omalizumab. Three types of response were evaluated: lower use of oral corticosteroids, improvement in lung function, and reduction in exacerbations. A total of 110 patients under treatment with omalizumab were included, with a mean age of 48 ± 16 years. After 12 months had elapsed, significant reductions were found in the number of exacerbations, use of oral cortico-steroids and doses of inhaled corticosteroids (p < 0.001). Lung function and asthma control improved significantly (p < 0.001; p = 0.004) and eosinophil levels were significantly reduced (p = 0.004). Low scores in the Asthma Control Test were associated with the oral corticosteroid-saving effect; lower previous FEV1 levels and absence of chronic obstructive pulmonary disease (COPD) were related to improvement in lung function, and prior FEV1 values higher than 80% and absence of gastroesophageal reflux disease (GERD) with a reduction in exacerbations. The results of this study confirm the clinical benefit obtained after the introduction of omalizumab and the possible predictive biomarkers of response to the treatment.
format Online
Article
Text
id pubmed-9962091
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99620912023-02-26 Impact of Omalizumab in Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study Rojo-Tolosa, Susana González-Gutiérrez, María Victoria Sánchez-Martínez, José Antonio Jiménez-Gálvez, Gonzalo Pineda-Lancheros, Laura Elena Gálvez-Navas, José María Jiménez-Morales, Alberto Pérez-Ramírez, Cristina Morales-García, Concepción Pharmaceutics Article Most patients with asthma can control their symptoms with a basic standard of medical care and with maintenance and rescue medication. However, between 5% and 10% of asthmatics worldwide do not achieve control of their symptoms and have recurrent exacerbations and respiratory difficulties. The objective of the study was the real-life evaluation of the clinical improvement of patients with severe eosinophilic asthma treated with omalizumab, together with the search for biomarkers associated with the response. An observational retrospective cohort study was conducted that included patients with severe uncontrolled allergic asthma being treated with omalizumab. Three types of response were evaluated: lower use of oral corticosteroids, improvement in lung function, and reduction in exacerbations. A total of 110 patients under treatment with omalizumab were included, with a mean age of 48 ± 16 years. After 12 months had elapsed, significant reductions were found in the number of exacerbations, use of oral cortico-steroids and doses of inhaled corticosteroids (p < 0.001). Lung function and asthma control improved significantly (p < 0.001; p = 0.004) and eosinophil levels were significantly reduced (p = 0.004). Low scores in the Asthma Control Test were associated with the oral corticosteroid-saving effect; lower previous FEV1 levels and absence of chronic obstructive pulmonary disease (COPD) were related to improvement in lung function, and prior FEV1 values higher than 80% and absence of gastroesophageal reflux disease (GERD) with a reduction in exacerbations. The results of this study confirm the clinical benefit obtained after the introduction of omalizumab and the possible predictive biomarkers of response to the treatment. MDPI 2023-02-04 /pmc/articles/PMC9962091/ /pubmed/36839845 http://dx.doi.org/10.3390/pharmaceutics15020523 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rojo-Tolosa, Susana
González-Gutiérrez, María Victoria
Sánchez-Martínez, José Antonio
Jiménez-Gálvez, Gonzalo
Pineda-Lancheros, Laura Elena
Gálvez-Navas, José María
Jiménez-Morales, Alberto
Pérez-Ramírez, Cristina
Morales-García, Concepción
Impact of Omalizumab in Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study
title Impact of Omalizumab in Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study
title_full Impact of Omalizumab in Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study
title_fullStr Impact of Omalizumab in Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study
title_full_unstemmed Impact of Omalizumab in Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study
title_short Impact of Omalizumab in Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study
title_sort impact of omalizumab in patients with severe uncontrolled asthma and possible predictive biomarkers of response: a real-life study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962091/
https://www.ncbi.nlm.nih.gov/pubmed/36839845
http://dx.doi.org/10.3390/pharmaceutics15020523
work_keys_str_mv AT rojotolosasusana impactofomalizumabinpatientswithsevereuncontrolledasthmaandpossiblepredictivebiomarkersofresponseareallifestudy
AT gonzalezgutierrezmariavictoria impactofomalizumabinpatientswithsevereuncontrolledasthmaandpossiblepredictivebiomarkersofresponseareallifestudy
AT sanchezmartinezjoseantonio impactofomalizumabinpatientswithsevereuncontrolledasthmaandpossiblepredictivebiomarkersofresponseareallifestudy
AT jimenezgalvezgonzalo impactofomalizumabinpatientswithsevereuncontrolledasthmaandpossiblepredictivebiomarkersofresponseareallifestudy
AT pinedalancheroslauraelena impactofomalizumabinpatientswithsevereuncontrolledasthmaandpossiblepredictivebiomarkersofresponseareallifestudy
AT galveznavasjosemaria impactofomalizumabinpatientswithsevereuncontrolledasthmaandpossiblepredictivebiomarkersofresponseareallifestudy
AT jimenezmoralesalberto impactofomalizumabinpatientswithsevereuncontrolledasthmaandpossiblepredictivebiomarkersofresponseareallifestudy
AT perezramirezcristina impactofomalizumabinpatientswithsevereuncontrolledasthmaandpossiblepredictivebiomarkersofresponseareallifestudy
AT moralesgarciaconcepcion impactofomalizumabinpatientswithsevereuncontrolledasthmaandpossiblepredictivebiomarkersofresponseareallifestudy